Eyewire Today http://eyewiretoday.com/ Eyewire Today en-us Tue, 13 Oct 2015 08:50:36 GMT Tue, 13 Oct 2015 08:50:36 GMT EyewireToday.com First US Patients Treated with Focused Ultrasound for Parkinson’s-Related Dyskinesia http://eyewiretoday.com/view.asp?url=20150902-first_us_patients_treated_with_focused_ultrasound_for_parkinsons-related_dyskinesia Researchers at the University of Maryland and the University of Virginia have performed the first focused ultrasound treatments in the United States for dyskinesia associated with Parkinsons disease. These treatments are part of international pilot s... Wed, 2 Sep 2015 16:07:00 GMT No Good Evidence to Support OTC Antioxidants in MS http://eyewiretoday.com/view.asp?url=20150824-no_good_evidence_to_support_otc_antioxidants_in_ms There is no clinical evidence to support recommendation of OTC antioxidant compounds for patients with MS, a new analysis shows. (Mult Scler., epub) However, preclinical evidence is potentially promising for epigallocatechin-3-gallate (ECGC) and (alp... Mon, 24 Aug 2015 21:11:00 GMT Evidence of Disease Activity in MS a Possible Marker of Treatment Effect http://eyewiretoday.com/view.asp?url=20150824-evidence_of_disease_activity_in_ms_a_possible_marker_of_treatment_effect RRMS patients who use more first line and less second line disease modifying treatment may be more like to show evidence of disease activity (EDA) compared to others with the disease, a new study suggests. (PLoS One, e-pub) In fact, at one year follo... Mon, 24 Aug 2015 21:08:00 GMT Small Bowel Feeding Bests Gastric Feeding For Severe TBI, New Analysis Finds http://eyewiretoday.com/view.asp?url=20150624-small_bowel_feeding_bests_gastric_feeding_for_severe_tbi_new_analysis_finds While there is no consensus for the preferred route of feeding following severe traumatic brain injury (TBI), new evidence suggests that small bowel feeding might be the preferred method over gastric feeding. Writing in the Journal of Neurosurgery, r... Wed, 24 Jun 2015 14:11:00 GMT NeuroDerm Poster Selected for Blue Ribbon Highlights Session: International Congress of Parkinson's Disease and Movement Disorders Annual Meeting http://eyewiretoday.com/view.asp?url=20150619-neuroderm_poster_selected_for_blue_ribbon_highlights_session_international_congress_of_parkinsons_disease_and_movement_disorders_annual_meeting NeuroDerm Ltd's poster presentation, "Stable levodopa plasma levels with ND0612 (LD/CDfor subcutaneous infusion) in Parkinson's disease (PD) patients with motor fluctuations" was part of the 19th International Congress of Parkinson's Disease and Mov... Fri, 19 Jun 2015 13:33:00 GMT Tool May Help MS Patients Assess Voice Quality http://eyewiretoday.com/view.asp?url=20150522-tool_may_help_ms_patients_assess_voice_quality The Voice Handicap Index (VHI) is an effective tool to assess patient self-perception of voice quality among MS patients (Int Arch Otorhinolaryngol. 2015 Apr;19(2):100-5). However, researchers showed that it may not reflect the severity of dysphonia ... Fri, 22 May 2015 15:55:00 GMT SWI Shows Promise for In-Vivo Study of EAE and MS http://eyewiretoday.com/view.asp?url=20150522-swi_shows_promise_for_in-vivo_study_of_eae_and_ms Researchers may be closer to using susceptibility-weighted imaging (SWI) to investigate the contribution of vascular-based hypointensities in experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (MS) over time. (PLoS One. 2015 ... Fri, 22 May 2015 15:36:00 GMT Most Women Don't Know Female-Specific Signs, Symptoms of Stroke http://eyewiretoday.com/view.asp?url=20150427-most_women_dont_know_female-specific_signs_symptoms_of_stroke A new survey shows that most women dont know the risks or symptoms females face when it comes to having a stroke.The survey of 1,000 women, compiled by researchers at The Ohio State University Wexner Medical Center, found that only 11 percent of wom... Mon, 27 Apr 2015 14:49:00 GMT Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-Lingo-1 Trial In People With Acute Optic Neuritis http://eyewiretoday.com/view.asp?url=20150108-biogen_idec_reports_positive_top-line_results_from_phase_2_anti-lingo-1_trial_in_people_with_acute_optic_neuritis Biogen Idec (NASDAQ: BIIB) today announced top-line results from the Phase 2 acute optic neuritis (AON) RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system. Anti-LINGO-1 demonstrated an improveme... Thu, 8 Jan 2015 14:33:00 GMT NeuroDerm: Phase IIa Data for SC levodopa/carbidopa Promising http://eyewiretoday.com/view.asp?url=20141230-neuroderm_phase_iia_data_for_sc_levodopacarbidopa_promising Continuous, subcutaneous delivery of NeuroDerm Ltd.'s proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels, the company says. The results, they say, suggest that t... Tue, 30 Dec 2014 13:41:00 GMT Athena Diagnostics to Present Original Research on Neurogenetics at American Academy of Neurology's 2014 Annual Meeting http://eyewiretoday.com/view.asp?url=20140501-athena_diagnostics_to_present_original_research_on_neurogenetics_at_american_academy_of_neurologys_2014_annual_meeting Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that several scientists from its Athena Diagnostics specialty neurology business will present research during the the American Academy of ... Thu, 1 May 2014 18:44:00 GMT Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the 66th Annual Meeting of the American Academy of Neurology http://eyewiretoday.com/view.asp?url=20140501-avanir_pharmaceuticals_announces_multiple_data_presentations_highlighting_its_central_nervous_system_cns_therapeutics_franchise_at_the_66th_annual_mee Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and migraine development programs will be presented at the 66th American Academy of Neurology (AA... Thu, 1 May 2014 15:25:00 GMT Sunovion Pharmaceuticals Inc. Presents Data on Aptiom® (eslicarbazepine acetate) at 66th American Academy of Neurology Annual Meeting http://eyewiretoday.com/view.asp?url=20140501-sunovion_pharmaceuticals_inc_presents_data_on_aptiom_eslicarbazepine_acetate_at_66th_american_academy_of_neurology_annual_meeting Thu, 1 May 2014 15:15:00 GMT Analysis: Spinal Cord Injuries Costly, Deadly http://eyewiretoday.com/view.asp?url=20131217-analysis_spinal_cord_injuries_costly_deadly Spinal cord injury-related hospitalizations cost Americans approximately $1.69 billion in 2009, a new analysis reveals. (Spinal Cord e-pub) Length of hospital stays for SCIs were 2.5 times higher than for non-SCI patients, and average charges were fo... Tue, 17 Dec 2013 14:12:00 GMT Non-apnea Sleep Disorders Associated with Stroke Risk http://eyewiretoday.com/view.asp?url=20131217-non-apnea_sleep_disorders_associated_with_stroke_risk Patients with nonapnea sleep disorders (NSD) are at increased risk for developing ischemic stroke, compared to patients without diagnosed sleep disorder, new data show. Men and the elderly are at greatest risk, according to the analysis in Sleep Medi... Tue, 17 Dec 2013 14:00:00 GMT Preliminary Results from WED/RLS “Patient Odyssey” Survey http://eyewiretoday.com/view.asp?url=20131115-preliminary_results_from_wedrls_patient_odyssey_survey The Willis-Ekbom Disease (WED) Foundation and XenoPort released preliminary results from the Patient Odyssey survey, which reveal the challenges experienced by patients with Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED). The survey kicked off... Fri, 15 Nov 2013 16:07:00 GMT New Tysabri® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity http://eyewiretoday.com/view.asp?url=20131003-new_tysabri_data_show_earlier_treatment_and_longer-term_use_result_in_significant_reductions_in_ms_disease_activity Biogen Idec (NASDAQ: BIIB) today announced results from several new analyses of TYSABRI (natalizumab) data that demonstrate its effectiveness in reducing multiple sclerosis (MS) disease activity. This effect was particularly significant in people wit... Thu, 3 Oct 2013 14:39:00 GMT New Guidelines Support Gabapentin Enacarbil for RLS/WED http://eyewiretoday.com/view.asp?url=20130926-new_guidelines_support_gabapentin_enacarbil_for_rlswed The updated treatment algorithm for patients with chronic persistent restless legs syndrome/Willis-Ekbom disease (RLS/WED) includes gabapentin enacarbil, the active ingredient in HORIZANT (gabapentin enacarbil) Extended-Release Tablets, XenoPort, Inc... Thu, 26 Sep 2013 14:10:00 GMT Migraine May be Common but Overlooked in Teen Girls http://eyewiretoday.com/view.asp?url=20130628-migraine_may_be_common_but_overlooked_in_teen_girls Up to 18 percent of teenage girls may have definite migraine, based on the International Headache Classification and 25 percent have probably migraine, a recent study published in the Journal of Pediatric Neurology suggests. Another 45 percent have n... Fri, 28 Jun 2013 05:26:00 GMT Ketogenic Diet May Aid Autism http://eyewiretoday.com/view.asp?url=20130628-ketogenic_diet_may_aid_autism A ketogenic diet may independently reduce behaviors associated with autism spectrum disorders, new research on mice suggests. Research has suggested that the 100-year old therapeutic diet may benefit neurological conditions besides epilepsy, includin... Fri, 28 Jun 2013 05:21:00 GMT ALS Research Make Promising Gene Discovery http://eyewiretoday.com/view.asp?url=20130628-als_research_make_promising_gene_discovery Researchers from Northwestern University's School of Medicine studying amyotrophic lateral sclerosis (ALS) have for the first time identified a gene both in motor neurons in the brain and spinal cord affected by ALS. The finding could lead the way to... Fri, 28 Jun 2013 05:14:00 GMT Glioma induced immunosuppression increases progression-free survival in a trial of immunotherapy for glioblastoma http://eyewiretoday.com/view.asp?url=20130503-glioma_induced_immunosuppression_shortens_progression-free_survival_in_a_trial_of_immunotherapy_for_glioblastoma Preliminary data from a Phase II clinical trial showed that newly diagnosed glioblastoma multiforme (GBM) patients treated with Prophage G-100 (Heat Shock Protein-Peptide Complex-96, HSPPC-96) vaccine plus the standard of care showed a 146 percent in... Fri, 3 May 2013 16:00:00 GMT Data: High Satisfaction Among PD Patients with GI Effects Switched to Neupro http://eyewiretoday.com/view.asp?url=20130320-data_released_on_switching_pd_patients_with_pre-existing_gastrointestinal_symptoms_from_oral_pd_medications_to_neupro New data from a non-interventional, observational study found that when Parkinsons disease (PD) patients were switched from an oral PD medication to Neupro (Rotigotine Transdermal System), they reported improvements in pre-existing gastrointestinal (... Wed, 20 Mar 2013 18:30:00 GMT Research uncovers a potential link between Parkinson’s and visual problems http://eyewiretoday.com/view.asp?url=20130219-research_uncovers_a_potential_link_between_parkinsons_and_visual_problems The most common genetic cause of Parkinsons is not only responsible for the conditions distinctive movement problems but may also affect vision, according to new research by scientists at the University of York. Tue, 19 Feb 2013 17:29:00 GMT New Study Focuses on Veterans with Epilepsy http://eyewiretoday.com/view.asp?url=20130219-new_study_focuses_on_veterans_with_epilepsy The Department of Veterans Affairs' Epilepsy Centers of Excellence (ECoE), biopharmaceutical company UCB, and health data-sharing website Patients Like Meare partnering on a new study they hope will further understanding of what factors improve healt... Tue, 19 Feb 2013 16:43:00 GMT